8-K - ENDV - Equibles

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM8-K

CURRENTREPORT

PURSUANTTO SECTION 13 OR 15(d) OF THE

SECURITIESEXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 2, 2020

$Z:\2020 OPERATIONS\2020 EDGAR\03 March\ENDONOVO THERAPEUTICS, INC\03-01-2020\Form 8-K\Draft\Production$

ENDONOVOTHERAPEUTICS, INC.

(Exactname of registrant as specified in its charter)

Delaware	000-55453	45-2552528
(State<br> or other jurisdiction<br><br> of incorporation)	(Commission<br><br> File Number)	(IRS<br> Employer<br><br> Identification No.)

6320Canoga Avenue, 15^th^ Floor

WoodlandHills, CA 91367

(Address of principal executive office)(Zip Code)

Registrant’s telephone number, including area code: (800) 489-4774

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ]	Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]	Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]	Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]	Pre-commencement<br> communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common<br> Stock, par value $0.0001 per share	ENDV	OTCQB

Item8.01 Other Events.

On March 2, 2020, the Registrant’s released a presentation on SofPulse® the company’s flagship Electrocuetical® device. The presentation will be utilized to expand the current US market rollout for SofPulse® and will be presented at various upcoming investment and medical conferences, seminars, presentations and institutional investor meetings.

Item9.01 Financial Statements and Exhibits.

(a) Financial Statements

None

(b) Exhibits

99.1 Presentation regarding SofPulse®.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 2, 2020

ENDONOVO THERAPEUTICS, INC.
By:	/s/ Alan Collier
	Alan<br> Collier
	Chief<br> Executive Officer

Exhibit 99.1